Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.

Segura-Sánchez J, González-Cámpora R, Pareja-Megia MJ, García-Escudero A, Galera-Ruiz H, López-Beltrán A.

Anticancer Res. 2006 Nov-Dec;26(6C):4937-42.

2.

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, Chibon F, Coindre JM, Pedeutour F.

Clin Cancer Res. 2009 Sep 15;15(18):5696-703. doi: 10.1158/1078-0432.CCR-08-3185. Epub 2009 Sep 8.

3.

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.

Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Mainguené C, Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P, Pedeutour F.

Int J Cancer. 2008 May 15;122(10):2233-41. doi: 10.1002/ijc.23380.

4.

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM.

Am J Surg Pathol. 2005 Oct;29(10):1340-7.

PMID:
16160477
5.
6.

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.

Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM.

J Clin Pathol. 2009 Dec;62(12):1127-35. doi: 10.1136/jcp.2009.070201.

PMID:
19946100
7.

Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.

Mariño-Enríquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X.

Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.

8.

Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.

He M, Aisner S, Benevenia J, Patterson F, Harrison LE, Hameed M.

Pathol Res Pract. 2009;205(6):386-94. doi: 10.1016/j.prp.2008.12.009. Epub 2009 Jan 30.

PMID:
19186005
9.

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D.

Lab Invest. 2011 Mar;91(3):392-403. doi: 10.1038/labinvest.2010.185. Epub 2010 Nov 8.

10.

Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?

Le Guellec S, Chibon F, Ouali M, Perot G, Decouvelaere AV, Robin YM, Larousserie F, Terrier P, Coindre JM, Neuville A.

Am J Surg Pathol. 2014 Mar;38(3):293-304. doi: 10.1097/PAS.0000000000000131.

PMID:
24525499
11.

Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.

Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F.

Mod Pathol. 2009 Nov;22(11):1477-88. doi: 10.1038/modpathol.2009.119. Epub 2009 Sep 4.

12.

Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.

Kammerer-Jacquet SF, Thierry S, Cabillic F, Lannes M, Burtin F, Henno S, Dugay F, Bouzillé G, Rioux-Leclercq N, Belaud-Rotureau MA, Stock N.

Hum Pathol. 2017 Jan;59:34-40. doi: 10.1016/j.humpath.2016.08.009. Epub 2016 Sep 3.

PMID:
27597521
13.

Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?

Italiano A, Cardot N, Dupré F, Monticelli I, Keslair F, Piche M, Mainguené C, Coindre JM, Pedeutour F.

Int J Cancer. 2007 Jul 15;121(2):308-15.

14.
15.

Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.

Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA.

J Pathol. 1998 Jun;185(2):188-90.

PMID:
9713346
16.

High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.

Lee SE, Kim YJ, Kwon MJ, Choi DI, Lee J, Cho J, Seo SW, Kim SJ, Shin YK, Choi YL.

Histol Histopathol. 2014 Jan;29(1):127-38. doi: 10.14670/HH-29.127. Epub 2013 Jul 15.

PMID:
23852861
17.

Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.

Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, Rao S, Pasquini G, Azzarelli A, Rilke F, Pierotti MA.

J Pathol. 1997 Jan;181(1):14-24.

PMID:
9071998
18.

Dedifferentiated liposarcoma with meningothelial-like whorls, metaplastic bone formation, and CDK4, MDM2, and p16 expression: a morphologic and immunohistochemical study.

Thway K, Robertson D, Thway Y, Fisher C.

Am J Surg Pathol. 2011 Mar;35(3):356-63. doi: 10.1097/PAS.0b013e31820832c1.

PMID:
21317707
19.

Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.

Chung L, Lau SK, Jiang Z, Loera S, Bedel V, Ji J, Weiss LM, Chu PG.

Am J Surg Pathol. 2009 Nov;33(11):1594-600. doi: 10.1097/PAS.0b013e3181accb01.

PMID:
19574885
20.

Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C, Château MC, Peoc'h M, Battistella M, Bazin A, Gal J, Michiels JF, Coindre JM, Pedeutour F, Bianchini L.

Mod Pathol. 2015 Nov;28(11):1404-14. doi: 10.1038/modpathol.2015.96. Epub 2015 Sep 4.

Supplemental Content

Support Center